Psilocybin therapy standardized for clinical depression shows large benefits in a randomized trial, with stronger effects than psychotherapy plus escitalopram

Psilocybin-assisted therapy for clinical depression shows substantial antidepressant effects in a standardized treatment model tested in a randomized controlled trial. Depression symptoms fell more after the psilocybin intervention than after a comparison treatment combining psychotherapy with the SSRI escitalopram, suggesting that a more manualized psychedelic protocol can still produce strong outcomes. The trial is notable because psychedelic therapy is often criticized for being too variable across therapists and settings to scale cleanly in mainstream medicine. Standardization matters for regulatory review, clinical training, and reproducibility, especially when treatment effects may depend on preparation, dosing support, and integration. The findings support the idea that psilocybin can be delivered within a structured clinical framework without losing much of its therapeutic impact. That raises the prospect of broader adoption in depression care if larger studies confirm safety, durability, and effectiveness across more diverse patient populations.